



Light Line has developed a patented, elegant, low-cost, and effective solution to prevent and treat catheter infections. Never done before, precision targeted visible light, generated by a laser, is delivered via a specially treated fiber optic cable inside an off-the-shelf catheter, thereby disinfecting it and preventing infection.

## Changing the Way the World Prevents Catheter Infections

### PROBLEM:

In the U.S. alone, infections caused by catheters result in \$50 billion of annual healthcare costs and 100,000 patient deaths per year due primarily to antibiotic resistant infections (i.e., MRSA and ERSA). *The current standard of care - sterile technique and/or antimicrobial coated catheters - is simply not effective.*

### SOLUTION: PLATFORM DISINFECTANT TECHNOLOGY FOR ALL CATHETERS:

Light Line Medical's (LLM) Visible Light Disinfectant data is conclusive. Without relying on drugs, chemicals, or harmful UV light (which degrades catheter materials and damages DNA), we kill fungus as well as drug resistant gram-positive and gram-negative bacteria thereby preventing catheter-associated infections. (Kill rate: > 99.99% required by FDA). LLM's solution is not impacted by antibiotic resistance, the 3rd leading cause of death worldwide.

### ATTRACTIVE INVESTMENT OPPORTUNITY

- **Total Addressable Market (TAM):** \$16 billion
- **Partnerships:** Mayo Clinic, Medline Industries (exclusive NA distributor of Light Line urinary product), in confidential discussions with public companies
- **Traction:** \$10+ Million invested by institutions (Merit Medical, Mayo Clinic), family offices, angel groups, doctors from Kaiser Permanente and Orlando Health and individuals. Grants & Awards: AMA, NASA, NSF, IBM, USPTO
- **Seasoned Team:** Vicki Farrar, CEO and Bob Hitchcock CTO Co-Founders of Catheter Connections (Sold to Merit Medical for 5X revenue)
- **Platform Technology:** Initial product for peritoneal dialysis catheter is non-invasive / no clinical studies required. Next: urinary, respiratory & vascular
- **Powerful Blocking Patents:** 30 Issued, 19 pending; Freedom to Operate opinions. IP covers method of delivery
- **Investment Target:** 32 to 54X the initial investment (based on acquisition for 3-5X projected revenue)
- **Revenue:** Targeting 80% gross margin
- **Competition:** Sterile technique and antimicrobial coated catheters are the current competition. Alone they are not effective. LLM's technology supplements these. Thus, catheter manufacturers are LLM's potential partners and acquirers.

### UNMATCHED VALUE PROPOSITION

- **Easy to use:** Can be used in hospital, clinic, or home with minimal training
- **Patient Doesn't Get an Infection, Caregiver Doesn't Treat an Infection**
- **Insurers are not Paying for Infections:** Healthcare associated infections should never happen; therefore, the insurers do not pay for them
- **Hospitals are not Financially Penalized for Infections:** Hospitals are assessed penalties based on the number of their hospital-acquired infections (In US >\$700M in hospital penalties annually)

### RAISING \$7M SERIES A -- \$1.2M AVAILABLE -- USE OF FUNDS:

- Conduct all PD FDA Testing Required
- PD 510(K) Submission Q4/2023
- Production Partner
- KOL Podium and Publication Strategy
- Build Out Team – Add Marketing, Sales, and Engineers
- Begin Foley Development – Most Common Healthcare Acquired Infection Worldwide